AXS-05 meets primary endpoint for Alzheimer’s disease agitation study: industry news round-up

This week in industry has seen various drugs meeting study endpoints and receiving US FDA approval. For example, AXS-05 meets its primary endpoint for Alzheimer’s disease (AD) agitation, ONGENTYS® receives US FDA approval as an add-on treatment for ‘OFF’ episodes in Parkinson’s disease (PD) and ocrelizumab may delay the risk of needing a walking aid in relapsing multiple sclerosis (MS). AXS-05 meets primary endpoint for Alzheimer’s disease agitation study ONGENTYS® receives US FDA approval as add-on treatment for ‘OFF’ episodes in Parkinson’s Ocrelizumab delays risk of needing walking aid in relapsing multiple sclerosis, new data reveals   AXS-05 meets primary...